GLP-1s and Your Body's "Set Point"

The "set point" is the idea that your body defends a particular weight range, fighting to pull you back whenever you stray with appetite and metabolic adjustments. GLP-1 medications appear to lower that defended weight while you take them, which is a big part of why they work, and also why weight often returns when you stop. Whether the lower point can be made to stick is still unsettled, but muscle and habits seem to help.

This article covers Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide). It is general education, not medical advice, and contains no dosing guidance. The set point is a model, a useful way to think, not a precise biological constant.

What "set point" actually means

The set point theory holds that your body behaves like a thermostat for weight. Drift too far below the temperature it wants, and it turns up hunger and turns down energy expenditure to bring you back.

When you lose weight, this defense is measurable. Ghrelin, a hunger hormone, tends to rise. Leptin, which signals satiety and fat stores, tends to fall. And your resting metabolism becomes more efficient, an effect called adaptive thermogenesis, burning fewer calories than your new smaller size alone would predict. Together these make a lower weight harder to reach and harder to hold.

It is worth being clear that "set point" is a model, not a hard law. The defended range is influenced by genetics, history, environment, and behavior, and it can move. But as a mental model for why weight resists change, it is genuinely useful.

How a GLP-1 appears to move the dial

A GLP-1 does not override your biology so much as lean on the appetite side of it. By amplifying satiety signals from the gut and brainstem and dampening the brain's reward response to food, the drug makes a lower intake feel comfortable that would otherwise trigger the body's defenses.

In effect, it lowers the weight your body actively defends, for as long as the drug is on board. A modeling study of GLP-1 physiology framed this precisely: semaglutide weakens the appetite feedback loop rather than eliminating it, so the system finds a new, lower equilibrium. That is why a GLP-1 can move you to a weight that was hard to reach and hold before, and it is the same reason the effect is tied to continued use.

The catch: what happens when you stop

If the lowered set point depended on the drug, then removing the drug should let the old defenses reassert. That is broadly what the data show.

In the STEP 1 extension, participants regained roughly two thirds of the weight they had lost within a year of stopping semaglutide, on average, when there was no structured maintenance plan. Cardiometabolic improvements largely reverted too. Appetite returns because the drug fades, and the body drifts back toward a higher defended weight. We cover this in depth in weight regain after stopping a GLP-1.

This is why GLP-1s are increasingly discussed like medications for a chronic condition, such as blood pressure or cholesterol drugs, where stopping tends to undo the benefit. Whether to stay on, lower the dose, or taper is a prescriber decision; we cover the phase in GLP-1 maintenance after goal weight.

Can you make a lower set point stick?

This is the open question, and the honest answer is "uncertain, and it varies." There is no strong evidence that a GLP-1 permanently resets the thermostat for everyone. But the picture is not hopeless, because some of what defends your weight is modifiable.

Two levers matter most.

First, muscle. Lean mass is metabolically active and raises your maintenance calorie needs, so more muscle means you can eat more at a given weight before regaining. Each kilogram of muscle you keep, rather than lose, raises the floor your body has to defend. That is a meaningful nudge in your favor over a lifetime, and it is exactly why losing muscle on the way down is so costly; see how much muscle you lose on Ozempic and Wegovy.

Second, habits. The eating patterns, protein intake, and training you build while on the drug are what can carry results afterward. Resistance training matters more after stopping, not less, because it is the signal that tells your body to keep the muscle that holds the line. See keeping your muscle after stopping a GLP-1.

Why muscle is the set-point lever you control

You cannot directly command your hypothalamus to defend a lower weight. But you can build the muscle that raises your maintenance calories, and you can keep the resistance-training and protein habits that defend that muscle.

A practical target during weight loss is roughly 1.2 to 1.6 g/kg of body weight per day of protein, per the 2025 joint advisory from the Obesity Medicine Association, The Obesity Society, the American Society for Nutrition, and the American College of Lifestyle Medicine, paired with regular strength training. That combination is the most controllable way to influence the long-term math. More in resistance training on a GLP-1.

Where Myo fits

The set point is invisible. You cannot see your defended weight, but you can see the one thing most under your control that moves it: your muscle. Since lean mass raises the weight your body can comfortably hold, Myo's lean-mass tracking shows you building the metabolic floor that makes a lower set point more likely to stick.

By trending your muscle alongside protein and resistance-training logs, Myo turns "I hope this stays off" into a visible record of whether you are building the foundation that holds. Body-composition tracking and the muscle-loss trend flag are part of Myo Premium; weight logging and the protein ring are free. You may not control the thermostat directly, but you can build the body that argues for a lower setting.

References

• GLP-1 weight-loss plateau physiology and appetite feedback modeling (lowered equilibrium, not eliminated): PMC10705578.
• Adaptive thermogenesis and hormonal compensation during weight loss: established caloric-restriction physiology.
• Weight regain after stopping semaglutide (~two thirds regained within a year): STEP 1 extension, Diabetes, Obesity and Metabolism 2022 (PubMed 35441470 / PMC9542252).
• Continued treatment maintains weight loss; withdrawal associated with regain: SURMOUNT-4 (PubMed 38078870).
• Lean-mass share of weight lost on GLP-1s (~25 to 40%): SURMOUNT-1 body-composition substudy (DOM 2025, doi:10.1111/dom.16275); STEP 1 and SUSTAIN 8 DXA analyses.
• Protein target during weight loss (~1.2 to 1.6 g/kg/day) and resistance training: 2025 joint advisory from OMA, TOS, ASN, and ACLM (PMC12264624).